Top

Journal of Neuro-Oncology

Published in:

01-05-2020 | Clinical Study

Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors

Authors: Lindsay A. Williams, Christopher L. Moertel, Michaela Richardson, Erin L. Marcotte

Published in: Journal of Neuro-Oncology | Issue 3/2020

Abstract

Background

The incidence of malignant peripheral nerve sheath tumors (MPNSTs) is low in the general population, although individuals with Neurofibromatosis Type I (NF1) are particularly susceptible. These tumors generally have a high probability of metastasis. The rate and types of second malignancies (SMNs) after a primary diagnosis of MPNST are not well characterized. We aimed to quantify the rate of SMNs among individuals with a first primary MPNST using population-based data.

Methods

We estimated age-standardized incidence rates (SIRs) for SMNs among 1,579 primary MPNST cases between ages 0–85+ using SEER 18 (2000–2015). We estimated incidence rate ratios (IRRs) and 95% confidence intervals (95% CI) for SMNs in MPNST cases compared with general population rates. We conducted sex-stratified and age-restricted analyses (< 30 years at diagnosis).

Results

Seven percent (108/1579) of MPNST cases developed a SMN (SIR of 4635 cases/million). Compared to the general population, MPNST cases were more likely to develop SMNs (IRR: 29.3; 95% CI 23.8–34.8) and had a much higher rate of second MPNSTs (IRR: 15,992.9; 95% CI 9594.5–22,391.3). Aside from a second MPNST, second cancers were frequently diagnosed in the breast, lung, skin, and soft tissue in females and were myeloid and skin malignancies in males. When restricted to < 30 years of age, second MPNSTs were the most common cancers diagnosed.

Conclusions

The rate of SMNs among MPNST cases is tremendously higher than that observed among individuals with other cancers, particularly for second MPNSTs. These findings suggest rates of SMNs may also be higher in NF1 individuals.

Available only for authorised users

Gupta G, Maniker A (2007) Malignant peripheral nerve sheath tumors. Neurosurg Focus 22(6):1–8. https://doi.org/10.5603/ocp.2018.0050 CrossRef

Hajdu SI (1993) Peripheral nerve sheath tumors histogenesis, classification, and prognosis. Cancer 72(12):3549–3552. https://doi.org/10.1002/1097-0142(19931215)72:12%3c3549:AID-CNCR2820721202%3e3.0.CO;2-Y CrossRefPubMed

Uusitalo E, Rantanen M, Kallionpää RA et al (2016) Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 34(17):1978–1986. https://doi.org/10.1200/JCO.2015.65.3576 CrossRefPubMed

Riccardi VM (1981) Von Recklinghausen neurofibromatosis. N Engl J Med 305(27):1617–1627. https://doi.org/10.1128/CMR.14.2.296 CrossRefPubMed

Anderson JL, Gutmann DH (2015) Neurofibromatosis type 1, 1st edn. Elsevier, Amsterdam

Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function. Cell 104(4):593–604. https://doi.org/10.1016/s0092-8674(01)00245-8 CrossRefPubMed

Mowery A, Clayburgh D (2019) Malignant peripheral nerve sheath tumors: analysis of the national cancer database. Oral Oncol 98(September):13–19. https://doi.org/10.1016/j.oraloncology.2019.09.010 CrossRefPubMed

Martin E, Wijnen MHWA, Flucke UE et al (2019) Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis : a nationwide cohort study. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.28138 CrossRefPubMed

Rasmussen SA, Friedman JM (2000) NF1 gene and neurofibromatosis 1. Am J Epidemiol 151(1):33–40. https://doi.org/10.1093/oxfordjournals.aje.a010118 CrossRefPubMed

10.

Seminog OO, Goldacre MJ (2013) Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer 108(1):193–198. https://doi.org/10.1038/bjc.2012.535 CrossRefPubMed

11.

Peltonen S, Kallionpää RA, Rantanen M et al (2019) Pediatric malignancies in neurofibromatosis type 1: a population-based cohort study. Int J Cancer 145(11):2926–2932. https://doi.org/10.1002/ijc.32187 CrossRefPubMedPubMedCentral

12.

Bhatia S, Chen Y, Wong FL et al (2019) Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1. J Clin Oncol 37(32):3050–3058. https://doi.org/10.1200/JCO.19.00114 CrossRefPubMed

13.

Sorensen SA, Mulvihill JJ, Nielsen A (1986) Long-term follow-up of von Recklinghausen Neurofirbromatosis. New Engl J Med 314(16):1010–1015. https://doi.org/10.1056/NEJM198107023050102 CrossRefPubMed

14.

Maris JM, Wiersma SR, Mahgoub N et al (1997) Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79(7):1438–1446. https://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3c1438:AID-CNCR22%3e3.0.CO;2-# CrossRefPubMed

15.

Evans D, Baser M, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311–314CrossRef

16.

Walker L, Thompson D, Easton D et al (2006) A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95(2):233–238. https://doi.org/10.1038/sj.bjc.6603227 CrossRefPubMedPubMedCentral

17.

Tora MS, Xenos D, Texakalidis P, Boulis NM (2019) Treatment of neurofibromatosis 1-associated malignant peripheral nerve sheath tumors: a systematic review. Neurosurg Rev. https://doi.org/10.1007/s10143-019-01135-y CrossRefPubMed

18.

Miao R, Wang H, Jacobson A et al (2019) Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol 137:61–70. https://doi.org/10.1016/j.radonc.2019.03.015 CrossRefPubMed

19.

Peckham-Gregory EC, Montenegro RE, Stevenson DA et al (2018) Racial/ethnic disparities and incidence of malignant peripheral nerve sheath tumors: results from the Surveillance, Epidemiology, and End Results Program, 2000–2014. J Neurooncol 139(1):69–75. https://doi.org/10.1007/s11060-018-2842-4 CrossRefPubMed

20.

Baehring JM, Betensky RA, Batchelor TT (2003) Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 61(5):696–698. https://doi.org/10.1212/01.WNL.0000078813.05925.2C CrossRefPubMed

21.

Korf BR (2000) Malignancy in neurofibromatosis type 1. Oncologist 5(6):477–485. https://doi.org/10.1634/theoncologist.5-6-477 CrossRefPubMed

22.

Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA (2012) Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 158(12):3061–3064. https://doi.org/10.1002/ajmg.a.35560 CrossRef

23.

Uusitalo E, Kallionpää RA, Kurki S et al (2017) Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer 116(2):211–217. https://doi.org/10.1038/bjc.2016.403 CrossRefPubMed

24.

Brown AL, Arroyo VM, Agrusa JE, Scheurer ME, Gramatges MM, Lupo PJ (2019) Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: a population-based assessment. Cancer 125(20):3623–3630. https://doi.org/10.1002/cncr.32356 CrossRefPubMed

25.

Turcotte LM, Neglia JP, Reulen RC et al (2018) Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: a review. J Clin Oncol 36(21):2145–2152. https://doi.org/10.1200/JCO.2017.76.7764 CrossRefPubMedPubMedCentral

26.

Turcotte LM, Liu Q, Yasui Y et al (2017) Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970–2015. JAMA 317(8):814–824. https://doi.org/10.1001/jama.2017.0693 CrossRefPubMedPubMedCentral

27.

Widemann BC (2009) Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 11(4):322–328. https://doi.org/10.1007/s11912-009-0045-z CrossRefPubMedPubMedCentral

28.

Valentin T, Le Cesne A, Ray-Coquard I et al (2016) Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 56:77–84. https://doi.org/10.1016/j.ejca.2015.12.015 CrossRefPubMed

29.

Martin E, Coert JH, Flucke UE et al (2020) A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer 124:77–87. https://doi.org/10.1016/j.ejca.2019.10.014 CrossRefPubMed

30.

van Noesel MM, Orbach D, Brennan B et al (2019) Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer 66(10):1–8. https://doi.org/10.1002/pbc.27833 CrossRef

31.

Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ (2009) Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. https://doi.org/10.1155/2009/756395 CrossRefPubMedPubMedCentral

32.

Watson KL, Al Sannaa GA, Kivlin CM et al (2017) Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg 126(1):319–329. https://doi.org/10.3171/2015.12.JNS152443 CrossRefPubMed

33.

Noone AM, Lund JL, Mariotto A et al (2016) Comparison of SEER treatment data with medicare claims. Med Care 54(9):e55–e64. https://doi.org/10.1097/MLR.0000000000000073 CrossRefPubMedPubMedCentral

Title: Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors
Authors: Lindsay A. Williams
Christopher L. Moertel
Michaela Richardson
Erin L. Marcotte
Publication date: 01-05-2020
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03478-9

At a glance: The STEP trials

Springer Medicine

Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma

Incidence of high grade gliomas presenting as radiographically non-enhancing lesions: experience in 111 surgically treated non-enhancing gliomas with tissue diagnosis

Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine

Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database

Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma

Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes